Celyad SA is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
In the following press release Dr. Christian Homsy, CEO of Celyad commented: “NKR-2 Phase I trial was a safety study with the primary objective of ensuring that there was no on-target, off-tumor toxicity. We are positively surprised at reports of unexpected clinical benefit, while testing just one single infusion dosed between 50 and 1,000 times lower than our expected efficacious dose extrapolated from animal experiments.” Read the full article.
Celyad SA is a clinical-stage biopharmaceutical company that engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. [Source: MarketWatch]
Company Website: http://www.celyad.com